<?xml version="1.0" encoding="UTF-8"?>
<p>In 2013, researchers from Riboxx GmbH (Germany) developed a modified method for producing PolyG:PolyC to overcome these drawbacks. The newÂ drug RGC100 was characterized by a strictly defined length (100 bp) and a chemical structure, good solubility and pronounced immunomodulatory activity, particularly, the ability to cause DC activation and T-cell proliferation [
 <xref ref-type="bibr" rid="CR46">46</xref>].
</p>
